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ABSTRACT  
Current treatments for Parkinson’s disease (PD) are aimed at addressing motor 
symptoms but there is no therapy focused on modifying the course of the disease. 
Successful treatment strategies have been so far limited and brain drug delivery remains 
a major challenge that restricts its treatment. This review provides an overview of the 
most promising emerging agents in the field of PD drug discovery, discussing 
improvements that have been made in brain drug delivery for PD. It will be shown that 
new approaches able to extend the length of the treatment, to release the drug in a 
continuous manner or to cross the blood brain barrier and target a specific region are 
still needed.  
Overall, the results reviewed here show that there is an urgent need to develop 
both symptomatic and disease-modifying treatments, giving priority to neuroprotective 
treatments. Promising perspectives are being provided in this field by rasagiline and by 
neurotrophic factors like glial cell line-derived neurotrophic factor. The identification of 
disease-relevant genes has also encouraged the search for disease-modifying therapies 
that function by identifying molecularly-targeted drugs. The advent of new molecular 
and cellular targets like α-synuclein, leucine-rich repeat serine/threonine protein kinase 
2 or parkin, among others, will require innovative delivery therapies. In this regard, 
drug delivery systems (DDS) have shown great potential for improving the efficacy of 
conventional and new PD therapy and reducing its side effects. The new DDS discussed 
here, which include microparticles, nanoparticles and hydrogels among others, will 
probably open up possibilities that extend beyond symptomatic relief. However, further 
work needs to be done before DDS become a therapeutic option for PD patients. 
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1 INTRODUCTION 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder, affecting 1.5% of the global population over 65 years of age. Pathologically, 
PD is characterized by the progressive degeneration of the nigrostriatal dopaminergic 
system, which causes dopamine (DA) loss. Symptomatically, PD is marked by the 
difficulty to perform coordinated movements. The core features are bradykinesia, 
resting tremor and rigidity. PD patients suffer from non-motor symptoms such as sleep 
disorders, neuropsychiatric issues and cognitive dysfunction [1, 2]. The current 
treatment, based on a DA replacement strategy, consists of the oral administration of the 
DA precursor levodopa (L-DOPA). However, its long-term administration produces 
severe detrimental L-DOPA-associated motor complications [3]. There is compelling 
evidence that L-DOPA-derived issues are associated with short-acting dopaminergic 
agents that induce pulsatile stimulation of the receptors [4, 5]. A continuous stimulation 
may result in better tolerability and fewer side effects [3, 5]. Thus, new approaches that 
can extend the length of the treatment or release the drug in a continuous manner are 
needed. Moreover, while motor effects of the disorder are, at least partially, being 
addressed with L-DOPA, alleviating non-motor symptoms is actually an unmet need. 
However, the development of a disease-modifying strategy able to slow or stop disease 
progression has become a priority. 
Crossing the blood brain barrier (BBB) remains a key obstacle in the 
development of effective PD treatments, as only small molecules with appropriate 
lipophilicity, molecular weight and charge are able to diffuse from blood into the central 
nervous system (CNS). Approaches to transport therapeutic molecules across the BBB 
have recently been reviewed by Gabathuler [6]. The most accepted method used to 
increase the transport of therapeutics from blood into the brain is the physiological 
approach which takes advantage of the receptor transcytosis capacity. Other strategies 
include drug manipulation, BBB disruption and finding alternatives routes for drug 
delivery [7]. In order to solve brain delivery issues, there has been growing interest in 
the development of micro and nanosystems for the administration of drugs into the brain 
tissue.  
This review provides a concise overview of the most promising emerging agents 
in the field of drug discovery for PD. The advances made in the last 5 years in brain 
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drug delivery for PD treatment are also discussed with the aim of improving both 
conventional and new PD therapies. 
 
2 SYMPTOMATIC AND DISEASE MODIFYING TREATMENTS FOR PD 
UNDER INVESTIGATION  
Drug development in PD is currently focused on: (i) reformulation of existing 
drugs (e.g. novel approaches for DA drug delivery including novel extended-release 
oral formulations), (ii) reposition of compounds approved for other indications such as 
the antiepileptic topiramate and (iii) development of novel small molecules and gene 
and cell-based approaches [8]. 
Most of these strategies are aimed at addressing motor symptom control and far 
fewer are focused on alleviating non-motor symptoms or on modifying the course of the 
disease [8]. For instance, at present there are 32 and 30 clinical trials open in phase III 
and IV respectively and none of these is evaluating neuroprotective strategies (source 
ClinicalTrials.gov). Regarding symptomatic therapy, rasagiline deserves special 
attention, as 3 of the 32 phase III trials and 7 of the 30 phase IV trials are evaluating its 
efficacy on different aspects of the disease such as apathy, depression, hyposmia, sleep 
disturbances, emotion or mood among other. It has recently been described that 
rasagiline may delay disease progression [9]. However, the clinical significance of these 
results is controversial. In this sense, there is one on-going Phase III clinical trial to 
evaluate rasagiline efficacy as a monoamine oxidase B inhibitor, and it is a candidate 
for phase II or III neuroprotective studies due to its anti-oxidant and anti-apoptotic 
properties (source ClinicalTrials.gov). 
Concerning neuroprotective treatments, the efficacy of neurotrophic factors (NF) 
such as glial cell line-derived neurotrophic factor (GDNF) or neurturine have been 
assessed in phase I and II clinical trials (revised in [10-12]. Their delivery to the brain 
remains a key issue and multiple approaches are being explored to overcome this 
problem (see the section 3.2.2). On the other hand, the identification of disease-relevant 
genes has encouraged the search for disease-modifying therapies by identifying 
molecularly-targeted drugs. New agents targeting α-synuclein, leucine-rich repeat 
serine/threonine protein kinase 2 and parkin appear to be the most promising 
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approaches. However, these discoveries are just the first step toward new treatments 
[13].  
It is expected that the advent of new molecular and cellular targets, together with 
advances in genomic and proteomic technologies, will increase the discovery of novel 
pharmaceutical compounds for PD treatment. However, many of the new developments 
will be biological therapies like proteins, cells or genes that will require innovative 
delivery methods. 
 
3 DRUG DELIVERY APPROACHES TO IMPROVE PD TREATMENT  
As described above, a list of PD therapies has been identified. However, drug delivery 
to the CNS remains a challenge in the development of effective treatments for PD. In 
order to solve brain delivery issues, there has been growing interest in the development 
of micro and nanosystems able to enhance brain delivery of drugs. DDS are capable of 
improving the pharmacological and therapeutic properties of conventional and new 
drugs, reducing their side effects. In the context of PD, DDS can be used either for local 
treatment administered directly into the brain or for systemic delivery for targeted action 
in the CNS. 
DDS can be biodegradable or non-biodegradable depending upon the nature of the 
polymer or the material used for its preparation. Among DDS, hydrogels and polymeric 
or lipid microparticles (MP) and nanoparticles (NP) seem to be the most effective in 
providing neuroprotection and facilitating the delivery of drugs and small molecules to 
the brain (Figure 1). 
In this section, the studies published in the last 5 years using DDS for PD treatment are 
reviewed (Table 1 and 2). 
3.1 SYSTEMIC DDS IN PD 
As far as systemic administration is concerned, it is important to consider not only the 
net delivery of the agent to the CNS, but also the drug ability to target the specific brain 
region (Table 1 and Figure 2).  
3.1.1 DSS FOR DOPAMINE DELIVERY 
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DA, due to its hydrophilic feature and its high hydrogen bonding potential, does 
not cross the BBB and its brain administration constitutes a challenge.  
De Giglio et al., [14] published DA-loaded chitosan NP (DA-Cs-NP) 
formulation and characterization. Chitosan was chosen due to its high loading and good 
delivery ability for hydrophilic molecules. In vitro studies confirmed that DA-Cs-NP 
were less cytotoxic than the free-drug. An improvement in DA transport across the cells 
and oxygen reactive species reduction after 3 hours was observed. In vivo microdialysis 
studies administrating intraperitoneal DA-Cs-NP demonstrated a dose- and time-
dependent striatal DA level increase [15]. 
An innovative tendency in drug development is the combination of a fluorescent 
compound with a therapeutic drug for simultaneous diagnosis and treatment. In this 
sense, Malvindi et al., [16] combined fluorescence quantum rods with an ester bond 
with succinyl DA which can be hydrolyzed by cellular enzymes to release the prodrug 
inside the cells. This DDS was covered with a galactose shell which can be recognized 
by the GLUT-1 transporters to mediate its diffusion across the BBB. In vitro studies 
confirmed a high NP internalization due to the interaction between the sugar and the 
GLUT-1 transporters. MTT viability tests confirmed that the carbohydrate shell 
significantly improved NP biocompatibility compared to the non-coated nanocrystals. 
The ability to preserve all these properties in vivo is currently being tested in murine 
models.  
DA have recently been conjugated with different aminoacid derivatives, used as 
prodrug molecular carriers to target the brain by using their ability to interact with the 
large aminoacid transporter I (LAT I) [17]. DA combined with phenylalanine derivative 
presented the highest affinity for LAT I receptor and the best brain uptake after 
intravenous administration. However, its intraperitoneal injection did not significantly 
increase DA striatal levels compared with L-DOPA treatment. 
3.1.2 DDS FOR LEVODOPA DELIVERY 
L-DOPA, a prodrug which is converted into DA in the brain, is the gold standard 
option in PD treatment. However, the oral bioavailability of this compound is low and 
has to be combined with carbidopa to avoid its peripheral degradation. 
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D´Aurizio et al. [18] synthesized the prodrug l-dopa-α-lipoic acid (LD-DA), a 
compound with longer plasma half-life than L-DOPA due to its lower susceptibility 
toward enzymatic conversion and higher lipophilicity that facilitates its delivery in the 
CNS. LD-DA was encapsulated in poly(lactic-co-glycolic acid) (PLGA) MP (LD-DA-
MP) obtaining successful prodrug enzymatic and chemical hydrolysis prevention, and 
presenting sustained release via Fickian diffusion for up to more than one week. In vivo 
LD-DA-MP subcutaneous administration induced high levels of striatal DA during 4 
days. 
Ren et al., [19] encapsulated L-DOPA methyl ester, a highly soluble prodrug 
hydrolysable by plasma esterases, together with benserazide, a peripheral decarboxylase 
inhibitor in PLGA MP (LP-be-MP). MP subcutaneously administered improved motor 
function and stepping of the lesioned forepaw in the 6-hydroxydopamine (6-OHDA) PD 
rat model. LP-be-NP were also able to significantly reduce the axial, limb, orolingual 
and locomotive L-DOPA-induced abnormal involuntary movements or dyskinesia in the 
same PD model, compared to the free drug [20]. L-DOPA-induced dyskinesia 
molecular markers were significantly reduced in the rats presenting involuntary 
movements and treated with LP-be-NP. 
Sharma et al. [21] developed a system with L-DOPA encapsulated in chitosan 
NP (LP-Cs-NP) and incorporated in a thermo-reversible Pluronic F127 gel for intranasal 
delivery. Polycation was used due to its mucoadhesive properties in addition to its 
ability to improve drug absorption on nasal mucosa by opening transiently tight 
junctions between epithelial cells and delaying mucociliary clearance. In vivo studies 
demonstrated that intranasally administered LP-Cs-NP significantly increased the drug 
brain content. LP-Cs-NP incorporation into the gel facilitated administration of the 
formulation and increased NP residence time in the nasal cavity. However, gel viscosity 
reduced NP migration, reducing its uptake, as the NP dispersed in saline solution 
intranasally administered elicited higher drug brain levels compared to the gel-
embedded NP.  
3.1.3 DDS FOR AGONIST DELIVERY 
The use of DA structural analogs is another therapeutic strategy to provide 
continuous DA receptor stimulation. Most agonists present low bioavailability when 
they are orally administered as free drugs and they have to be administered daily in 
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several doses, since their effect lasts only a short time. They are thus good candidates 
for being formulated in DDS. With this aim, Wang et al., [22] developed rotigotine 
loaded PLGA MP (Ro-MP) for the continuous release of this D1/D2/D3 DA agonist. 
The pharmacokinetic study revealed high and stable plasma and striatal drug levels for 
up to 14 days, as determined by microdialysis in 6-OHDA-lesioned rats. Ro-MP 
intramuscularly injected combined with pulsatile L-DOPA treatment induced 
significantly less dyskinesias in rats than the pulsatile L-DOPA monotherapy, although 
both treatments exerted a similar therapeutic motor effect. The toxicity of MP loaded 
with different drug concentrations was further evaluated in a 3-month study in monkeys. 
The toxicological effects were associated with rotigotine pharmacodynamic properties 
and with the foreign body reaction against PLGA and carboxymethylcellulose sodium, 
used as MP vehicle. The authors concluded that, at the end of the study, MP exhibited 
high safety in the monkey model. Toxicological findings recovered to a normal level 
except for adrenal gland vacuolar degeneration [23]. 
Regnier-Deplace et al., [24] encapsulated the D1/D2 DA receptor agonist 
apomorphine in PLGA MP. The labile drug was effectively protected against 
degradation during MP preparation. The formulation showed a constant drug release 
rate for about 10 days.  
Tsai et al. [25] encapsulated apomorphine in solid lipid NP of tripalmitin and 
hydrogenated soybean phosphatidylcholine for oral administration. After NP 
characterization, pharmacokinetic studies were carried out in rats comparing the oral 
formulation administration with the intravenous drug injection. Drug bioavailability was 
increased with the NP at all times. Apomorphine concentrations in plasma, cerebellum, 
brainstem and striatum were higher in NP-treated rats. The formulation efficacy was 
evaluated in vivo according to its ability to improve parkinsonian rat rotational behavior. 
Animals treated with orally administered NP presented significant differences in the 
total rotation number compared to those treated with drug solution. 
Azeem et al. [26] developed a nanoemulsion gel for ropinirole transdermal 
delivery. Pharmacokinetic studies using different nanoemulsions revealed significantly 
greater drug release, absorption and bioavailability from the DDS compared to the 
conventional gel and to the orally administered marketed drug tablet suspension. These 
effects were attributed to the hepatic first-pass metabolism bypass. The lack of 
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histological injuries on the rat skin after the nanoemulsion application supports the view 
that the formulation is safe. The efficacy of the formulations was tested by analyzing 
three biochemical markers of oxidative stress in the 6-OHDA-lesioned rat striatum. 6-
OHDA induced a significant increase in thiobarbituric acid reactive substances and a 
significant decrease in reduced glutation levels and catalase activity. Biochemistry 
parameters were significantly reversed and improved after the transdermal 
administration of the nanoemulsion, which also presented significantly better results 
compared to oral administration of the drug in tablets.  
Chitosan NP were developed for intranasal delivery of bromocriptine [27]. NP 
were characterized, presenting a size of 160 nm which is compatible with transcellular 
transport through olfactory neurons to the brain. The mucoadhesive strength was 
demonstrated in vitro by studying mucin binding efficiency to the NP. Intranasal 
administration of radiolabelled drug formulations compared to free solution allowed 
biodistribution and pharmacokinetic studies in mice, confirming a significant increase in 
drug brain uptake when the drug was encapsulated in the mucoadhesive NP, and direct 
transport to the brain. The efficacy of the DA agonist was tested in a haloperidol-
induced PD animal model. Bromocriptine in solution or nanoencapsulated was 
administered through the nostrils 15 minutes after the oral administration of haloperidol. 
The agonist was able significantly to reverse catalepsy and akinesia induced by 
haloperidol, producing better results with the nanoencapsulated drug. 
3.1.4 DDS FOR ANTIOXIDANT DELIVERY 
The antioxidant drug tempol was encapsulated in PLGA NP. OX-26 antibody 
was conjugated to the particles (Te-OX-NP) to enhance NP CNS delivery. NP have a 
size of 80–110 nm, suitable for BBB permeation. In vitro studies confirmed that 
antibody addition increased NP incorporation by the cells. Cell viability studies 
established that Te-OX-NP were more effective in preventing cell death induced by 
toxics substances than Te-NP or than the free drug in solution [28]. 
3.1.5 DDS FOR PROTEIN INHIBITORS, PEPTIDES AND NEUROTROPHIC 
FACTOR DELIVERY 
The second generation monoamine oxidase MAO-B inhibitor rasagiline was 
encapsulated in PLGA MP. In vitro release studies demonstrated constant rasagiline 
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release for two weeks and a neuroprotective effect in neuronal-like cells treated with 
hydrogen peroxide. MP efficacy was tested in the rotenone-induced PD model. 
Although non-statistically significant differences were found between the free drug and 
MP regarding behavioral parameters, the controlled rasagiline release allowed a better 
administration regimen, which is in itself one of the goals of encapsulation [29].  
Hu et al. [30] conjugated biodegradable PEG-PLGA NP with lactoferrin (Lf-
NP), a glycoprotein whose receptor transports Lf across the BBB in different species, 
obtaining a DDS with a particle size around 90 nm suitable for brain capillary cell 
endocytosis. In vitro studies encapsulating a fluorescence probe demonstrated that NP 
incorporation into the cells was mediated by clathrin-related endocytosis. After the 
intravenous administration through the mouse caudal vein of the probe encapsulated in 
Lf-NP or in normal NP, three times more fluorescent probe was present in the substantia 
nigra and striatum of Lf-NP injected animals. However, Lf-NP administration caused 
?mild transient acute? inflammatory reactions in liver, spleen and kidney. Lf-NP were 
further used for encapsulation of urocortin, which is a drug able to provide long-term 
nigrostriatal function restoration. Ur-Lf-NP intravenously administered significantly 
attenuated 6-OHDA-induced lesion evaluated using motor test and histological studies. 
This group also explored the intranasal drug delivery. For this purpose, PEG-PLGA NP 
were conjugated to odorranalectin (Ol-NP) to improve nose-to-brain drug delivery [31]. 
In vitro hemagglutination test studies using red blood cells confirmed that the lectin 
maintained its bioactivity after NP formulation. The biodistribution of Ol-NP compared 
to normal NP was determined by encapsulating a fluorescent dye after intranasal 
administration in mice. Ol-NP fluorescence intensity in the brain was statistically 
stronger than the non-coated NP in the first 4 to 8 hours after administration. Urocortin 
was also used as drug model to test this system’s efficacy. Urocortin encapsulation in 
Ol-NP and its intranasal administration enhanced the drug’s neuroprotective effects as 
confirmed in hemiparkinsonian 6-OHDA rats. 
In contrast to conventional drugs focused on relieving PD symptoms, 
neurotrophic factors have been proposed as an alternative therapy to prevent or slow 
down disease progression. For this purpose, nerve growth factor was adsorbed on 
poly(butylcyanocrylate) NP coated with polysorbate-80 to facilitate the brain carrier 
transport. NP intravenously administered significantly increased GF brain concentration 
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[32] and induced a significant PD symptom reduction in a 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model.  
Polymeric NP are being investigated as potential non-viral vectors for efficient 
brain-targeting gene delivery. With this aim, Huang et al., used PANAM/PEG NP 
coated with Lf and encapsulating GDNF gene. Multiple NP intravenous administration 
presented neuroprotective effects in two different PD animal models, as confirmed by 
the significantly improved locomotor activity, reduced dopaminergic neuronal loss and 
enhanced monoamine neurotransmitter levels of the lesioned rats (33, 34). 
3.2 LOCAL DDS IN PD  
The direct drug injection to the brain was first used owing to the difficulty of 
targeting specific brain regions via the vascular route. Drug delivery directly to the brain 
can circumvent the BBB and release the drug directly to an intracranial target. DDS can 
be injected by stereotaxy in discrete, precise and functional brain areas without 
damaging the surrounding tissue. Treatment strategies aimed at local drug delivery have 
been markedly used since the advent of polymer-based particulate systems (Table 2 and 
Figure 2).  
3.2.1 DDS FOR DOPAMINE DELIVERY 
In order to restore striatal DA content, Pillay et al. developed an intracranial 
nano-enabled scaffold device (NESD) for DA site-specific delivery [35]. The NESD 
was modulated through biometric simulation and computational prototyping to produce 
a binary crosslinked alginate scaffold embedding stable DA-loaded cellulose acetate 
phthalate NP. The NESD improved DA delivery to the brain in a rat model. DA 
concentrations in plasma were minimal and could reduce the profile of side-effects 
compared to orally administered L-DOPA due to peripheral conversion of L-DOPA to 
DA. 
3.2.2 DDS FOR NEUROTROPHIC FACTOR DELIVERY 
The potential of GDNF to alleviate symptoms and to slow or even halt PD 
progression is widely acknowledged [11, 12]. Equally, it is generally accepted that 
successful translation of GDNF to clinical practice will first require resolving the crucial 
delivery issues posed by NF. Different strategies including direct gene transfer using 
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recombinant virus (For review see [12]) and polymeric MP has been proposed to 
improve protein delivery to the brain [11, 36]. All research using GDNF-PLGA-MP in 
rat PD models reported animal functional recovery together with increase in striatal 
DArgic innervation [36, 37]. In the next step, our recent studies evaluating GDNF-MP 
efficacy in a primate PD model demonstrated that long-term controlled brain delivery of 
microencapsulated GDNF induced functional and structural recovery of the 
dopaminergic nigrostriatal pathway (Unpublished results). No apparent safety concern 
after GDNF-MP putaminal delivery was observed. None of the macaques showed 
weight loss, a common side effect observed after GDNF administration. These studies 
demonstrated that MP are an efficient vehicle for sustained neurotrophic factor delivery 
to the brain.  
In order to regulate the NF release from MP, Gujral et al. developed 
PLGA/collagen MP that encapsulated GDNF fused with collagen binding peptide [38]. 
MP with an outer layer of PLGA and an inner layer of collagen were able to control the 
release of the NF from the MP. Promising results were obtained in vitro, but this 
strategy needs in vivo validation before being applied in clinical settings.  
Combinatorial approaches delivering several growth factors at relevant 
therapeutic times and locations without toxic side effects have started to be researched. 
For instance, Herran et al. [39] investigated the neuroregenerative potential of PLGA 
microencapsulated VEGF, GDNF and their combination in a severely lesioned rat 
model. Both GDNF alone and the combination of GDNF and VEGF demonstrated 
regenerative effects. In a different study, Lampe et al. [40] assessed protein distribution 
and glial response after dual GDNF and BDNF delivery to the brain via PLGA MP 
patterned within a degradable polyethylene glycol (PEG)-based hydrogel. PEG-based 
hydrogels loaded with BDNF or GDNF locally released the respective NFs and were 
biocompatible with the brain tissue. Further studies are required to characterize this 
strategy’s effectiveness in brain regeneration. 
PLGA-MP encapsulating NF has also been proposed as scaffold for stem cell 
therapy/delivery. Recently, the efficacy of MIAMI cells, a mesenchymal stem cell 
subpopulation conveyed by neurotrophin-3 releasing MP, was assessed in a PD rat 
model. Functional recovery together with nigrostriatal pathway protection/repair was 
observed [41]. 
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Plasmid DNA encoding for GDNF was compacted into DNA NP using 
polycations to form colloidally stable NP. NP were then injected into the denervated 
striatum of rats with unilateral 6-OHDA lesion in order to enhance grafted DA neuron 
survival. Data suggest that compacted pGDNF could transfect cells to overexpress 
GDNF protein at levels that provide support for grafted stem cells [42]. 
3.2.3 OTHER DDS  
The sialic acid was embedded in a poly (N(2-hydroxypropyl) methacrylamide 
hydrogel, developed to interact with the damaged neural tissue and to promote tissue 
formation and axonal regeneration. The sialyl lactose hydrogel was characterized in 
vitro and implanted into the brain in an experimental PD model to examine its 
biofunctionality [43]. The hydrogel provided a three-dimensional substrate for cell 
migration, tissue remodeling and angiogenesis, demonstrating great potential. 
4 CONCLUDING REMARKS  
There is an urgent need to develop both symptomatic and disease-modifying 
treatments, the neuroprotective ones currently being considered the most important. 
However, most of the new drugs under clinical trials are related to last generation 
dopaminergic agonist administration. In addition, in the research field of DDS for 
systemic delivery, a considerable proportion of the recent studies still deal with the 
treatment of motor symptoms and only a few studies focus on the reversal of the 
neurodegenerative process (Figure 2). 
New extended-release formulations are a promising approach to improve L-
DOPA therapy. In this respect, research efforts have focused on new strategies to more 
effectively deliver drugs to the CNS. DDS might improve L-DOPA efficacy as well as 
the value of the new molecules currently being tested in clinical trials. However, while 
the efficacy of some DDS is currently being assessed in clinical trials for cancer and 
some of them have reached the market, DDS for PD are still in their infancy. It is 
remarkable that most of the DDS studies discussed here have been performed in rodent 
models of the disease and only a few of them have been carried out in preclinical animal 
models, like parkinsonian monkeys, which are the most clinically relevant of all 
available models. At present, the more advanced innovative treatments for PD are 
transdermal patches and extended release tablets. Thus, although initial progress has 
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been made, significant additional work is required before one of these promising 
strategies will be available in clinical practice.  
It is likely that future approaches in research on PD treatment will combine 
continuous dopaminergic stimulation obtained with L-DOPA derivatives or DA agonist, 
together with antioxidant molecules and a cocktail of different NF, probably all of them 
combined in a smart DDS conjugated with specific ligands to deliver all these protected 
compounds in a controlled and extended manner in the basal ganglia. 
New animal models able to completely recapitulate all the disease features, and a 
general consensus to use the same model to compare novel formulation efficacy, are 
also needed. Additionally, new clinical trial designs that include objective end-points 
for studies testing the efficacy of neuroprotective agents are required. To this end, 
innovative clinical trial designs have been proposed such as the delayed-start and 
futility designs. Finally, a better understanding of PD’s etiology together with the 
development of effective biomarkers would also help us to make progress in developing 
new forms of treatment. 
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FIGURE LEGENDS 
Figure 1: Schematic representation of the drug delivery systems under investigation for 
Parkinson’s disease. 
Figure 2: Pyramid representation of the percentage of studies published in the last five 
years using local or systemic drug delivery systems for Parkinson’s disease. 
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Table 1: Studies published in the last 5 years using systemic drug delivery systems for 
Parkinson’s disease treatment.  
Drug DDS Material Targeting 
ligand 
Administration 
route 
Animal 
model 
PD  
Ref 
Dopamine NP Chitosan    14 
Dopamine NP Chitosan  Intraperitoneal  15 
Succinyl 
Dopamine 
Nanotool  Galactose   16 
Dopamine Molecular carrier  Aminoacid 
derivatives 
Intraperitoneal  17 
L-dopa-α-lipoic 
acid 
MP PLGA  Subcutaneous  18 
Levodopa 
methyl ester + 
Benserazide 
(decarboxylase 
inhibitor) 
MP PLGA  Subcutaneous 6-OHDA 19  
Levodopa 
methyl ester + 
Benserazide 
(decarboxylase 
inhibitor) 
NP PLGA  Subcutaneous 6-OHDA 20 
Levodopa NP  
thermoreversible 
gel 
Chitosan  Intranasal  21 
Rotigotine 
(agonist) 
MP PLGA  Intramuscular 6-OHDA 22 
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Rotigotine 
(agonist) 
MP PLGA  Intramuscular  23 
Apomorphine 
(agonist) 
MP PLGA    24 
Apomorphine 
(agonist) 
Solid lipid 
nanoparticles 
Tripalmitin 
hydrogenat
ed soybean 
phosphatidi
lcholine 
 Oral 6-OHDA 25 
Ropinirole 
(agonist) 
Nanoemulsion   Transdermal 6-OHDA 26 
Bromocriptine 
(agonist and 
antioxidant) 
NP Chitosan   Intranasal Haloperid
ol 
 
27 
Tempol 
(antioxidant) 
NP PLGA Ab OX-26 
Transferrin 
receptor 
  28 
Rasagiline 
(MAO-B 
inhibitor) 
MP PLGA  Intraperitoneal 
 
Rotenone 29 
Urocortin NP PEG-
PLGA 
Lactoferrin Intravenous 
 
6-OHDA 30 
Urocortin NP PEG-
PLGA 
Odorranalectin Intranasal 6-OHDA 31 
NGF NP Poly 
butylcyano
crylate 
Polysorbate-80 Intravenous 
 
MPTP 32 
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GDNF NP PANAM/P
EG 
Lactoferrin Intravenous 
 
6-OHDA 33 
GDNF NP PANAM/P
EG 
Lactoferrin Intravenous 
 
Rotenone 34 
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Table 2: Studies published in the last 5 years using systemic drug delivery systems for 
Parkinson’s disease treatment. 
 
DRUG MATERIAL ANIMAL MODEL REF 
Dopamine Alginate scaffold embedding stable 
DA-loaded cellulose acetate 
phatalate nanoparticles 
Healthy Sprague-
Dawley rats 
35 
GDNF PLGA 6-OHDA rat model  36 and 37 
GDNF fused with 
collagen binding 
peptide 
PLGA/collagen In vitro 38 
GDNF and BDNF PLGA microparticles within a PEG-
based hydrogel 
In vitro 40 
GDNF and VEGF PLGA 6-OHDA rat model 39 
Neurotrophin-3 and 
MIAMI stem cells 
PLGA microparticles with a 
biomimetic surface 
6-OHDA rat model 41 
Plasmid GDNF DNA compacted by polycations to 
form colloidally stable nanoparticles 
6-OHDA rat model 42 
Sialic Acid Poly (N(2-hydroxypropyl) 
methacrylamide  
6-OHDA rat model 43 
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